Healthcare / Medical DevicesNasdaqGM
$0.90
-0.07 (-7.22%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 23%
FCF escenarios
weak_data · normalized FCF $-41.5M · quality 46.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
20/100
D
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$40M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-615.1%
↓Gross Margin
67.7%
↑Debt/Equity
8.90
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
+44.4%
FCF CAGR
—
FCF margin
-35.7%
FCF / Net income
0.74x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $80.3M · net income $-38.8M · FCF $-28.7M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $80.3M | $80.3M | $69.3M | $58.5M | $41.4M | $29.5M | $18.2M | $15.4M | $8.3M | $4.2M |
| Net Income | $-38.8M | $-38.8M | $-37.8M | $-46.7M | $-44.3M | $-33.3M | $-28.8M | $-22.4M | $-21.1M | $-21.3M |
| EBITDA | $-32.3M | $-32.3M | $-31.7M | $-40.6M | $-39.1M | — | — | — | — | — |
| EPS | — | — | -1.33 | -2.04 | -2.72 | -2.30 | -2.23 | -17.10 | — | — |
| Gross Margin | 67.7% | 67.7% | 67.1% | 68.6% | 65.3% | 63.9% | 61.7% | 60.0% | 35.6% | 59.6% |
| Operating Margin | -42.0% | -42.0% | -60.2% | -75.4% | -94.2% | -100.0% | -138.8% | -124.1% | -214.9% | -398.7% |
| Net Margin | -48.4% | -48.4% | -54.6% | -79.8% | -106.9% | -112.9% | -158.1% | -145.2% | -254.9% | -502.6% |
| Balance Sheet | ||||||||||
| Debt/Equity | 8.90 | 8.90 | 1.46 | 2.18 | 2.81 | 1.57 | 0.63 | 0.98 | — | — |
| Current Ratio | 3.61 | 3.61 | — | — | — | — | — | — | — | — |
| Cash Flow | ||||||||||
| Free Cash Flow | $-28.7M | $-28.7M | $-42.6M | $-41.5M | $-42.6M | $-31.1M | $-24.6M | $-25.7M | $-20.0M | $-16.5M |
| Returns | ||||||||||
| ROE | -615.1% | -615.1% | -133.0% | -247.1% | -309.7% | -165.6% | -58.7% | -72.4% | 15.3% | 19.7% |
| Valuation | ||||||||||
| P/B | 6.35 | 6.35 | 2.92 | 8.33 | 13.67 | — | — | — | — | — |
| Growth & Yield | ||||||||||
| Revenue Growth | 15.8% | 15.8% | 18.6% | 41.1% | — | 61.8% | 17.9% | 86.7% | 94.9% | — |
| EPS Growth | — | — | 34.8% | 25.0% | — | -3.1% | 87.0% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-35.3%
Start / end P/E
n/dx → n/dx
EPS bridge
-1.33 → n/d
Residual
-35.3%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.